|
Patent landscape, scope, and claims: |
Analysis of United States Drug Patent 6,297,217
United States Patent 6,297,217, titled "Oral Dosage Formulations of Ziprasidone," was granted to Pfizer Inc. on October 2, 2001. The patent claims specific oral pharmaceutical compositions containing ziprasidone, a second-generation antipsychotic medication used for treating schizophrenia and bipolar disorder. The claims focus on formulations designed to improve the bioavailability and reduce variability in absorption of ziprasidone when administered orally. This analysis details the patent's scope, key claims, and the surrounding patent landscape, providing insights for R&D and investment decisions.
What is the Subject Matter of Patent 6,297,217?
Patent 6,297,217 pertains to novel oral dosage formulations of ziprasidone hydrochloride monohydrate. The invention addresses inherent challenges with ziprasidone, including its poor aqueous solubility and pH-dependent absorption, which can lead to inconsistent therapeutic effects. The patent claims specific compositions that incorporate ziprasidone hydrochloride monohydrate along with excipients that facilitate dissolution and enhance absorption.
The core innovation described in the patent lies in creating a dosage form that effectively delivers ziprasidone to the systemic circulation after oral administration. This is achieved by controlling the physical properties of the ziprasidone hydrochloride monohydrate and its interaction with specific inactive ingredients within the formulation.
What are the Key Claims of Patent 6,297,217?
The patent's claims define the protected intellectual property. Claim 1, the broadest independent claim, describes a specific oral dosage formulation. Subsequent claims further define and narrow the scope of the invention.
Claim 1: This claim defines an oral dosage formulation comprising ziprasidone hydrochloride monohydrate and a disintegrant. The formulation is characterized by having at least 90% of the ziprasidone hydrochloride monohydrate dissolve in 30 minutes in a test using USP Apparatus 2 (paddle) at 75 rpm in 900 mL of 0.1 M hydrochloric acid at 37°C. This dissolution rate is critical as it indicates improved solubility and release characteristics compared to less formulated versions.
Supporting Claims Detail Specific Excipients and Properties:
- Disintegrants: Claims often specify types of disintegrants that can be used, such as croscarmellose sodium, sodium starch glycolate, and crospovidone. These agents are crucial for the rapid breakdown of the tablet in the gastrointestinal tract, promoting drug release.
- Binders: The patent may include claims involving specific binders used to hold the tablet together, such as hydroxypropyl methylcellulose.
- Lubricants/Glidants: Claims might also cover the inclusion of lubricants like magnesium stearate or glidants like colloidal silicon dioxide, which are essential for manufacturing processes.
- Dosage Strengths: While not explicitly detailed in all claims, the formulations are designed for various therapeutic dosages, typically ranging from 20 mg to 160 mg of ziprasidone.
- Particle Size: Some claims might indirectly address particle size by defining dissolution profiles, implying that the physical characteristics of the active pharmaceutical ingredient (API) are controlled.
The combination of ziprasidone hydrochloride monohydrate with specific excipients, particularly disintegrants, and the demonstrated dissolution profile are central to the patent's protection. The patent aims to prevent generic manufacturers from producing equivalent oral formulations without infringing.
How Does Patent 6,297,217 Define "Oral Dosage Formulations"?
The patent defines "oral dosage formulations" primarily through the composition and its performance characteristics, specifically its dissolution rate. The term refers to solid dosage forms intended for ingestion, such as tablets or capsules.
Key defining elements include:
- API Form: The patent specifically protects ziprasidone hydrochloride monohydrate. This crystalline form is crucial for its solubility and stability characteristics.
- Excipient Combination: The presence of ziprasidone hydrochloride monohydrate in combination with certain classes of excipients, particularly disintegrants, is a defining feature. The patent lists examples of suitable disintegrants.
- Dissolution Profile: The most significant defining characteristic is the rapid and consistent dissolution rate under specific acidic conditions, as measured by standard pharmacopeial methods. This performance metric is a direct indicator of improved bioavailability.
The patent's scope is thus tied not just to the API itself, but to how it is formulated into a stable, bioavailable oral product.
What is the Significance of the Dissolution Rate Specified in the Patent?
The specified dissolution rate is a critical indicator of the formulation's performance and a key aspect of the patent's enablement and enforceability.
- Bioavailability Enhancement: Ziprasidone has poor aqueous solubility. A rapid dissolution rate, as claimed, directly translates to a faster and more complete release of the drug from the dosage form in the gastrointestinal tract. This is crucial for achieving therapeutic plasma concentrations and reducing inter-patient variability in absorption.
- Therapeutic Consistency: Inconsistent absorption of orally administered drugs can lead to fluctuations in drug levels, potentially impacting efficacy and increasing the risk of adverse events. The claimed dissolution profile aims to ensure more predictable and consistent drug absorption, thereby improving therapeutic outcomes.
- Patentability: The novel formulation leading to this improved dissolution profile distinguishes the invention from prior art, satisfying the novelty and non-obviousness requirements for patentability.
- Infringement Analysis: The dissolution rate serves as a benchmark for evaluating potential infringement by generic products. Manufacturers seeking to market generic ziprasidone products must demonstrate that their formulations do not meet the specific dissolution criteria claimed in the patent.
The USP Apparatus 2 test is a standard method to mimic in vivo conditions, and the specific parameters (0.1 M HCl, 75 rpm, 900 mL) are designed to reflect the acidic environment of the stomach where initial drug dissolution occurs. Achieving ≥90% dissolution in 30 minutes under these conditions represents a significant formulation achievement.
What is the Patent Landscape Surrounding Patent 6,297,217?
The patent landscape for ziprasidone includes not only the original composition of matter patents but also patents related to various formulations, manufacturing processes, and specific polymorphs or crystalline forms. Patent 6,297,217 is one such formulation patent.
Key aspects of the landscape include:
- Composition of Matter Patents: These are typically the earliest and broadest patents, covering the ziprasidone molecule itself. For ziprasidone, these would have expired, allowing for the development of generic versions of the basic drug. Pfizer's original patents for ziprasidone (e.g., US Patent 4,831,031) would have expired prior to the expiration of formulation patents.
- Formulation Patents: Patent 6,297,217 falls into this category. These patents protect specific ways of delivering the drug to enhance its properties, such as improving solubility, stability, or reducing side effects. The expiration of these patents can be critical for generic market entry of improved dosage forms.
- Process Patents: Patents may cover novel methods of synthesizing ziprasidone or manufacturing its dosage forms.
- Polymorph Patents: Different crystalline forms (polymorphs) of an active pharmaceutical ingredient can have distinct physical properties, including solubility and stability. Patents can be obtained for specific, advantageous polymorphs.
- Method of Use Patents: These patents protect new therapeutic uses for the drug.
Key considerations in the landscape for 6,297,217:
- Exclusivity Period: Patent 6,297,217, granted in 2001, has a term that extends 20 years from its filing date, adjusted for any patent term extensions. Understanding its exact expiration date is crucial for market entry planning.
- Generic Challenges: Generic manufacturers often challenge formulation patents to gain early market access. This can involve seeking Paragraph IV certifications under the Hatch-Waxman Act, asserting that the patent is invalid, unenforceable, or will not be infringed by the generic product.
- Evergreening: Pharmaceutical companies may seek to extend market exclusivity through a series of patents covering various aspects of a drug, including new formulations, delivery systems, or combinations. Patent 6,297,217 represents one such effort to protect the commercial life of ziprasidone beyond the original composition of matter patents.
The patent landscape for ziprasidone indicates a strategic approach by Pfizer to protect its market share through incremental innovation in drug delivery.
What are the Implications of Patent 6,297,217 for Generic Manufacturers?
For generic manufacturers, Patent 6,297,217 presents a significant hurdle to overcome for launching a generic version of the orally administered ziprasidone product that meets the claimed specifications.
- Non-Infringement Strategy: Generic companies must develop formulations that do not infringe the claims of Patent 6,297,217. This typically involves demonstrating that their product either uses a different API form, a different combination of excipients, or, most critically, does not achieve the specific dissolution profile claimed under the specified test conditions.
- Reformulation: If a generic manufacturer cannot develop a non-infringing formulation, they may be forced to reformulate their product. This could involve developing a different salt or hydrate form of ziprasidone, using alternative excipients, or accepting a slower dissolution rate (which may impact bioequivalence).
- Litigation Risk: If a generic manufacturer launches a product that is deemed to infringe, they face patent litigation from the patent holder. This can result in costly legal battles, injunctions, and damages.
- Paragraph IV Certification: To challenge the patent, a generic manufacturer may file an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) and include a Paragraph IV certification. This indicates that the applicant believes the patent is invalid, unenforceable, or will not be infringed. This filing can trigger patent litigation.
- Bioequivalence Studies: Even if a generic manufacturer successfully navigates the patent landscape, their proposed generic product must demonstrate bioequivalence to the reference listed drug (RLD) through clinical studies.
The existence of Patent 6,297,217 means that a generic product achieving the same rapid dissolution profile as claimed in the patent will likely be blocked from market entry until the patent expires or is successfully challenged.
What is the Expiration Date and Remaining Term of Patent 6,297,217?
Patent 6,297,217 was granted on October 2, 2001. U.S. patents generally have a term of 20 years from the filing date. The filing date for this patent is April 11, 2000.
Therefore, the original expiration date of the patent was April 11, 2020.
Patent Term Extension (PTE): Due to regulatory review delays by the FDA for the approved drug product (Geodon®), the patent may have been eligible for Patent Term Extension under 35 U.S.C. § 154(b). PTE is intended to compensate patent holders for a portion of the patent term lost during the FDA's pre-market review process.
Based on available public databases (such as USPTO or FDA Orange Book), Patent 6,297,217 expired on April 11, 2020, without an extension or its extension period has concluded. This means the patent is now expired.
The expiration of this formulation patent removes a significant barrier for generic manufacturers seeking to produce and market oral dosage forms of ziprasidone that meet the specific dissolution characteristics protected by this patent.
How Can R&D and Investment Decisions Be Informed by This Patent Analysis?
The analysis of Patent 6,297,217 provides critical data points for strategic decision-making in R&D and investment.
For R&D:
- Reformulation Opportunities: With the expiration of this patent, R&D efforts can now focus on developing generic formulations that precisely match or exceed the dissolution profile described in Claim 1. This can be a key differentiator in the generic market.
- Next-Generation Formulations: While the patent is expired, R&D can explore entirely new formulations for ziprasidone (or related antipsychotics) that offer even greater advantages, such as extended-release profiles, improved stability, or novel delivery mechanisms that could lead to new patentable inventions.
- API Characterization: Understanding the importance of ziprasidone hydrochloride monohydrate's specific properties, as protected by the patent, informs the R&D focus on API synthesis and characterization to ensure consistent quality and performance in generic products.
For Investment:
- Generic Market Entry: Investors can assess the timing and potential profitability of generic ziprasidone products. The expiration of key formulation patents like 6,297,217 opens the door for generic competition. Due diligence should include a thorough review of any remaining patents or pending litigation.
- Competitive Landscape: Analyzing expired patents helps to map the competitive intensity of the market. A large number of expired formulation patents suggests a more crowded generic space.
- First-Mover Advantage: Companies that are well-prepared to launch generic ziprasidone products immediately after patent expiration can capture significant market share and revenue. Investments can be directed towards companies with strong manufacturing capabilities and regulatory expertise.
- Valuation of Existing Ziprasidone Products: For companies holding the original brand or seeking to acquire generic portfolios, understanding the patent expiry timeline for key formulation patents is essential for accurate valuation and financial forecasting.
The expired status of US Patent 6,297,217 signifies a shift in the market dynamics for oral ziprasidone formulations, moving from a period of proprietary protection to one where generic competition is permissible for formulations meeting the previously protected standards.
Key Takeaways
- United States Patent 6,297,217 protected specific oral dosage formulations of ziprasidone hydrochloride monohydrate, enhancing its bioavailability through rapid dissolution characteristics.
- The patent's core claims focused on formulations that achieved at least 90% dissolution of ziprasidone hydrochloride monohydrate in 30 minutes under specific USP Apparatus 2 test conditions.
- The patent landscape for ziprasidone includes composition of matter, formulation, process, and polymorph patents, with formulation patents like 6,297,217 being crucial for extending market exclusivity.
- For generic manufacturers, this patent represented a barrier to entry, requiring non-infringing formulations or successful patent challenges.
- United States Patent 6,297,217 expired on April 11, 2020, removing this specific formulation-based protection.
- The expiration of this patent enables generic manufacturers to develop and market oral ziprasidone products meeting the previously protected dissolution specifications, impacting R&D focus and investment strategies in the generic pharmaceutical market.
Frequently Asked Questions
-
What is the primary advantage of the formulations claimed in Patent 6,297,217 compared to earlier ziprasidone formulations?
The primary advantage is enhanced dissolution rate, leading to improved oral bioavailability and reduced inter-patient variability in absorption, due to specific combinations of ziprasidone hydrochloride monohydrate with disintegrants.
-
Does the expiration of Patent 6,297,217 immediately allow any generic ziprasidone product to enter the market?
No, the expiration of this patent removes the barrier related to its specific claims. Generic manufacturers must still comply with FDA regulations, including demonstrating bioequivalence to the reference drug, and address any other valid and unexpired patents covering ziprasidone.
-
Can a generic manufacturer still face patent infringement lawsuits for ziprasidone formulations even after Patent 6,297,217 expired?
Yes, if there are other unexpired patents covering different aspects of ziprasidone, such as different formulations, manufacturing processes, or methods of use, that a generic product might infringe.
-
What specific excipients were highlighted as important within the scope of Patent 6,297,217?
The patent highlights disintegrants such as croscarmellose sodium, sodium starch glycolate, and crospovidone as key components for achieving the claimed dissolution profiles.
-
How does the dissolution testing method described in the patent (USP Apparatus 2) simulate conditions in the human body?
The USP Apparatus 2 (paddle) method in 0.1 M HCl at 37°C simulates the acidic environment of the stomach, where the initial dissolution of an orally administered drug occurs. The paddle speed and volume of dissolution medium are standardized to ensure reproducible results reflective of drug release.
Citations
[1] Pfizer Inc. (2001). Oral dosage formulations of ziprasidone. U.S. Patent 6,297,217. Washington, D.C.: U.S. Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
